Inno-Gene 대차 대조표 상태

재무 상태 기준 확인 4/6

Inno-Gene 의 총 주주 지분은 PLN2.8M 이고 총 부채는 PLN30.0K, 이는 부채 대 자기자본 비율을 1.1% 로 가져옵니다. 총자산과 총부채는 각각 PLN5.5M 및 PLN2.7M 입니다.

주요 정보

1.1%

부채 비율

zł30.00k

부채

이자 보상 비율	n/a
현금	zł1.59m
주식	zł2.81m
총 부채	zł2.69m
총 자산	zł5.50m

최근 재무 상태 업데이트

업데이트 없음

Recent updates

재무 상태 분석

단기부채: IGN 의 단기 자산 ( PLN3.0M )이 단기 부채( PLN2.5M ).

장기 부채: IGN 의 단기 자산( PLN3.0M )이 장기 부채( PLN203.0K ).

부채 대 자본 내역 및 분석

부채 수준: IGN 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: IGN 의 부채 대 자기자본 비율은 지난 5년간 24.2% 에서 1.1% 로 감소했습니다.

부채 범위: IGN 의 영업현금흐름이 마이너스이므로 부채가 제대로 상환되지 않습니다.

이자 보장: IGN 의 부채에 대한 이자 지급이 EBIT에 의해 잘 충당되었는지 판단할 데이터가 부족합니다.

Inno-Gene 대차 대조표 상태

재무 상태 기준 확인 4/6

주요 정보

최근 재무 상태 업데이트

Recent updates

New major risk - Shareholder dilution

Inno-Gene S.A. announced that it expects to receive PLN 14.25 million in funding

Second quarter 2024 earnings released

Inno-Gene S.A., Annual General Meeting, Aug 13, 2024

Inno-Gene S.A. to Report Q4, 2023 Results on Jun 30, 2024

First quarter 2024 earnings released

Full year 2023 earnings released: zł0.26 loss per share (vs zł0.35 loss in FY 2022)

Inno-Gene S.A. to Report Q2, 2024 Results on Aug 09, 2024

Inno-Gene S.A. announced that it expects to receive PLN 1 million in funding

New major risk - Revenue and earnings growth

Inno-Gene S.A., Annual General Meeting, Sep 27, 2023

Inno-Gene S.A. to Report Fiscal Year 2022 Results on Aug 31, 2023

Inno-Gene S.A. to Report Fiscal Year 2022 Results on Jul 31, 2023

First quarter 2023 earnings released

Full year 2022 earnings released: EPS: zł0.058 (vs zł1.08 in FY 2021)

Inno-Gene S.A. to Report Q3, 2023 Results on Nov 09, 2023

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released

Investor sentiment deteriorated over the past week

Here's Why We Think Inno-Gene (WSE:IGN) Might Deserve Your Attention Today

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Inno-Gene S.A., Annual General Meeting, Jun 30, 2022

Inno-Gene S.A. (WSE:IGN) acquired additional 10.72% minority stake in Naturativ for PLN 0.01 million.

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Here's Why We Think Inno-Gene (WSE:IGN) Is Well Worth Watching

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Inno-Gene S.A. to Report Q3, 2022 Results on Nov 14, 2022

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Here's Why I Think Inno-Gene (WSE:IGN) Is An Interesting Stock

Investor sentiment deteriorated over the past week

Should You Be Adding Inno-Gene (WSE:IGN) To Your Watchlist Today?

Second quarter 2021 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2021 earnings released

We Wouldn't Rely On Inno-Gene's (WSE:IGN) Statutory Earnings As A Guide

Full year 2020 earnings released: EPS zł0.84 (vs zł0.029 loss in FY 2019)

New 90-day low: zł19.70

Inno-Gene S.A. to Report Q3, 2021 Results on Nov 12, 2021

New 90-day low: zł21.00

President of the Management Board recently sold zł3.2m worth of stock

New 90-day high: zł30.00

New 90-day low - zł10.00

Inno-Gene S.A. (WSE:IGN) acquired unknown stake in INNGEN SA for PLN 0.01 million.

First half earnings released

New 90-day high - zł19.25

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기